Literature DB >> 2845286

Inhibition of (+)[3H]SKF 10,047 binding to rat brain membranes by FAB fragments from a monoclonal antibody directed against the opioid receptor.

C B Tyler1, J M Bidlack.   

Abstract

Examination of the binding of (+)[3H]SKF 10,047 to rat brain membranes indicated that at a low concentration most of the binding was to the haloperidol-sensitive binding site. Titration curves exhibited a displacement potency order of haloperidol greater than (+)SKF 10,047 = 1,3-diorthotolyl-guanidine much much greater than (-)SKF 10,047 much greater than phencyclidine analogues. The effect of Fab fragments from a monoclonal antibody, OR-689.2.4, directed against the opioid receptor on the binding of (+)[3H]SKF 10,047 to rat brain membranes was examined. The specificity of this antibody for the opioid receptor has been determined by its ability to inhibit the binding of mu and delta opioid peptides to rat brain but not the binding of kappa opioid ligands or nonopioid ligands specific for other receptors. The Fab fragments blocked and displaced specifically bound (+)[3H]SKF 10,047 in a titratable manner. Increasing the incubation time of the membranes with the Fab fragments increased the percent inhibition obtained. The Fab fragments acted as noncompetitive inhibitors of (+)[3H]SKF 10,047 binding. A (+)SKF 10,047 binding site in rat brain appears to share a common structural domain with mu and delta opioid receptors.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2845286     DOI: 10.1007/bf00971595

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  34 in total

1.  The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog.

Authors:  W R Martin; C G Eades; J A Thompson; R E Huppler; P E Gilbert
Journal:  J Pharmacol Exp Ther       Date:  1976-06       Impact factor: 4.030

2.  Stereotyped behavior correlates better than ataxia with phencyclidine-receptor interactions.

Authors:  P C Contreras; K C Rice; A E Jacobson; T L O'Donohue
Journal:  Eur J Pharmacol       Date:  1986-02-11       Impact factor: 4.432

3.  (+)-[3H]SKF 10,047, (+)-[3H]ethylketocyclazocine, mu, kappa, delta and phencyclidine binding sites in guinea pig brain membranes.

Authors:  S W Tam
Journal:  Eur J Pharmacol       Date:  1985-02-12       Impact factor: 4.432

4.  Evidence for multiple opiate receptor involvement in different phencyclidine-induced unconditioned behaviors in rats.

Authors:  B D Greenberg; D S Segal
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

5.  Pharmacological and autoradiographic discrimination of sigma and phencyclidine receptor binding sites in brain with (+)-[3H]SKF 10,047, (+)-[3H]-3-[3-hydroxyphenyl]-N-(1-propyl)piperidine and [3H]-1-[1-(2-thienyl)cyclohexyl]piperidine.

Authors:  B L Largent; A L Gundlach; S H Snyder
Journal:  J Pharmacol Exp Ther       Date:  1986-08       Impact factor: 4.030

6.  Interaction of phencyclidine ("angel dust") with a specific receptor in rat brain membranes.

Authors:  J P Vincent; B Kartalovski; P Geneste; J M Kamenka; M Lazdunski
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

7.  Effects of phencyclidine, N-allyl-N-normetazocine (SKF-10,047), and verapamil on performance in a radial maze.

Authors:  D J McCann; J C Winter
Journal:  Pharmacol Biochem Behav       Date:  1986-02       Impact factor: 3.533

8.  Stereoisomers of N-allylnormetazocine: phencyclidine-like behavioral effects in squirrel monkeys and rats.

Authors:  K T Brady; R L Balster; E L May
Journal:  Science       Date:  1982-01-08       Impact factor: 47.728

9.  Stereoselective behavioral effects of N-allylnormetazocine in pigeons and squirrel monkeys.

Authors:  J L Katz; R D Spealman; R D Clark
Journal:  J Pharmacol Exp Ther       Date:  1985-02       Impact factor: 4.030

10.  Characterization of specific binding sites for [3H](d)-N-allylnormetazocine in rat brain membranes.

Authors:  Y Itzhak; J M Hiller; E J Simon
Journal:  Mol Pharmacol       Date:  1985-01       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.